公开(公告)号：US20150283134A1

公开(公告)日：2015-10-08

申请号：US14744103

申请日：2015-06-19

Applicant: H. Lundbeck A/S

Inventor： John Paul Kilburn ,  Lars Kyhn Rasmussen ,  Mikkel Jessing ,  Eman Mohamed Eldemenky ,  Bin Chen ,  Yu Jiang ,  Allen T. Hopper

IPC: A61K31/505

CPC classification number: A61K31/505 ,  C07C233/66 ,  C07C233/73 ,  C07C233/75 ,  C07C233/78 ,  C07C2601/08 ,  C07D211/26 ,  C07D213/40 ,  C07D213/61 ,  C07D231/12 ,  C07D233/64 ,  C07D237/08 ,  C07D239/26 ,  C07D241/12 ,  C07D309/04 ,  C07D401/06 ,  C07D403/04 ,  C07D403/06 ,  C07D405/04 ,  C07D405/06

Abstract: The present invention is directed to benzamide containing compounds which inhibit the P2X7 receptor

Abstract translation: 本发明涉及抑制P2X7受体的含苯甲酰胺的化合物

公开(公告)号：US20150175584A1

公开(公告)日：2015-06-25

申请号：US14574425

申请日：2014-12-18

Applicant: H. LUNDBECK A/S

Inventor： Jan Kehler ,  Lars Kyhn Rasmussen ,  Morten Langgard

IPC: C07D405/12

CPC classification number: C07D405/12

Abstract: The present invention provides Quinazolin-THF-amines as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

Abstract translation: 本发明提供Quinazolin-THF-胺作为PDE1抑制剂及其作为药物的用途，特别是用于治疗神经变性疾病和精神障碍。

公开(公告)号：US20150045348A1

公开(公告)日：2015-02-12

申请号：US14374278

申请日：2013-01-25

Applicant: H. Lundbeck A/S

Inventor： Niels Svenstrup ,  Klaus Bæk Simonsen ,  Lars Kyhn Rasmussen ,  Karsten Juhl ,  Morten Langgärd ,  Kate Wen ,  Yazhou Wang

IPC: C07D487/04

CPC classification number: C07D487/04 ,  A61K31/53

Abstract: This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).

Abstract translation: 本发明涉及PDE9酶抑制剂的化合物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明还提供制备式（I）化合物的方法。 本发明还提供了治疗患有神经变性疾病的受试者的方法，其包括给予受试者治疗有效量的式（I）化合物。 本发明还提供了治疗患有精神障碍的受试者的方法，其包括向受试者施用治疗有效量的式（I）化合物。

公开(公告)号：US20140107335A1

公开(公告)日：2014-04-17

申请号：US14050466

申请日：2013-10-10

Applicant: H. Lundbeck A/S

Inventor： John Paul Kilburn ,  Lars Kyhn Rasmussen ,  Mikkel Jessing ,  Eman Mohammed Eldemenky ,  Bin Chen ,  Yu Jiang

IPC: C07D295/13 ,  C07D239/26 ,  C07D211/38 ,  C07D413/06 ,  C07D403/06 ,  C07D401/06 ,  C07D213/40 ,  C07D267/10

CPC classification number: A61K31/553 ,  A61K31/40 ,  A61K31/445 ,  A61K31/4453 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/506 ,  A61K31/5375 ,  A61K31/5377 ,  A61K31/625 ,  C07D209/52 ,  C07D211/38 ,  C07D213/40 ,  C07D239/26 ,  C07D267/10 ,  C07D295/13 ,  C07D401/06 ,  C07D403/06 ,  C07D413/06

Abstract: The present invention is directed to novel cyclic amines which inhibit the P2X7 receptor.

Abstract translation: 本发明涉及抑制P2X7受体的新型环胺。